1.
Food and Drug Administration, Center for Drug Evaluation and Research (CDER) In
Vitro
Drug
Interaction
Transporter-Mediated
Studies
Drug
Cytochrome
Interactions
P450
Guidance
Enzymefor
and
Industry
https://www.fda.gov/media/134582/download January 2020
2.
Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
Clinical
Drug
Interaction
Transporter-Mediated
Drug
Studies
Cytochrome
Interactions
P450
Guidance
Enzymefor
and
Industry
https://www.fda.gov/media/134581/download January 2020
3.
European Medicines Agency, Committee for Human Medicinal Products (CHMP)
Guideline
on
the
Investigation
of
Drug
Interactions
https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-d
rug-interactions-revision-1_en.pdf June 2012
4.
独立行政法人医薬品医療機器総合機構 医薬品開発と適正な情報提供のための薬物相互作
用ガイドライン https://www.pmda.go.jp/files/000225191.pdf 2018. 7
5.
Maeda K. Organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 as
important regulators of the pharmacokinetics of substrate drugs Biol Pharm Bull. 2015;
38(2) :155-68.
6.
Patel M, Taskar KS, Zamek-Gliszczynski MJ. Importance of Hepatic Transporters in
Clinical Disposition of Drugs and Their Metabolites J Clin Pharmacol. 2016 Jul;56
Suppl 7:S23-39.
108
7.
International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, et al.
Membrane
transporters
in
drug
development
Nat Rev Drug Discov. 2010
Mar;9(3) :215-36.
8.
Shitara Y, Maeda K, Ikejiri K, et al. Clinical significance of organic anion transporting
polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal
absorption Biopharm Drug Dispos. 2013 Jan;34(1) :45-78.
9.
Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug--drug interactions
involving OATP substrates: predictions based on in vitro inhibition studies Clin
Pharmacol Ther. 2012 Jun;91(6) :1053-64.
10. Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between
HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin
Pharmacokinet. 2013 Oct;52(10) :815-31.
11. Tamraz B, Fukushima H, Wolfe AR, et al. OATP1B1-related drug–drug and drug–gene
interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
Pharmacogenet Genomics. 2013 Jul;23(7) :355-64.
12. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1
polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and
nateglinide. J Clin Pharmacol. 2008 Mar;48(3) :311-21.
13. Han JY, Lim HS, Shin ES, et al. Influence of the organic anion-transporting polypeptide
1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of
patients with advanced non-small cell lung cancer. Lung Cancer. 2008 Jan;59(1) :69-75.
14. Vaidyanathan J, Yoshida K, Arya V, Zhang L. Comparing Various In Vitro Prediction
Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion
Transporting Polypeptide 1B1 J Clin Pharmacol. 2016 Jul;56 Suppl 7:S59-72.
109
15. Rodrigues AD, Taskar KS, Kusuhara H, Sugiyama Y. Endogenous Probes for Drug
Transporters:
Balancing
Vision
With
Reality.
Clin
Pharmacol
Ther.
2018
Mar;103(3) :434-448.
16. International Transporter Consortium, Chu X, Liao M, Shen H, et al. Clinical Probes
and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction
Evaluation: Perspectives From the International Transporter Consortium. Clin
Pharmacol Ther. 2018 Nov;104(5) :836-864.
17. van de Steeg E, Wagenaar E, van der Kruijssen CM, et al. Organic anion transporting
polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile
acids, and drugs. J Clin Invest. 2010 Aug;120(8) :2942-52.
18. Chu X, Shih SJ, Shaw R, et al. Evaluation of cynomolgus monkeys for the identification
of endogenous biomarkers for hepatic transporter inhibition and as a translatable
model to predict pharmacokinetic interactions with statins in humans. Drug Metab
Dispos. 2015 Jun;43(6) :851-63.
19. Yee SW, Giacomini MM, Hsueh CH, et al. Metabolomic and Genome-wide Association
Studies Reveal Potential Endogenous Biomarkers for OATP1B1. Clin Pharmacol Ther.
2016 Nov;100(5) :524-536.
20. Watanabe M, Watanabe T, Yabuki M, Tamai I. Dehydroepiandrosterone sulfate, a useful
endogenous probe for evaluation of drug-drug interaction on hepatic organic anion
transporting polypeptide (OATP) in cynomolgus monkeys. Drug Metab Pharmacokinet.
2015 Apr;30(2) :198-204.
21. Bednarczyk D, Boiselle C. Organic anion transporting polypeptide (OATP) -mediated
transport of coproporphyrins I and III. Xenobiotica. 2016; 46(5) :457-66.
110
22. Lai Y, Mandlekar S, Shen H, et al. Coproporphyrins in Plasma and Urine Can Be
Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by
Organic Anion Transporting Polypeptide Inhibition. J Pharmacol Exp Ther. 2016
Sep;358(3) :397-404.
23. Shen H, Dai J, Liu T, et al. Coproporphyrins I and III as Functional Markers of
OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species. J Pharmacol
Exp Ther. 2016 May;357(2) :382-93.
24. Shen H, Christopher L, Lai Y, et al. Further Studies to Support the Use of
Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for
Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. Drug Metab
Dispos. 2018 Aug;46(8) :1075-1082.
25. Shen H, Chen W, Drexler DM, et al. Comparative Evaluation of Plasma Bile Acids,
Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with
Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug
Metab Dispos. 2017 Aug;45(8) :908-919.
26. Jirsa M, Knisely AS, Schinkel A, Kmoch S. Rotor Syndrome. GeneReviews®
https://www.ncbi.nlm.nih.gov/books/NBK114805/ University of Washington, Seattle;
1993-2020.
27. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal
physiology and liver disease. Gastroenterology. 2004 Jan;126(1) :322-42.
28. Tsuruya Y, Kato K, Sano Y, et al. Investigation of Endogenous Compounds Applicable to
Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1
and OAT3, in Humans. Drug Metab Dispos. 2016 Dec;44(12) :1925-1933.
111
29. Stieger B. The role of the sodium-taurocholate cotransporting polypeptide (NTCP)
and
of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation.
Handb Exp Pharmacol. 2011; (201) :205-59.
30. Dong Z, Ekins S, Polli JE. Quantitative NTCP pharmacophore and lack of association
between DILI and NTCP Inhibition. Eur J Pharm Sci. 2015 Jan 23;66:1-9.
31. Hachad H, Ragueneau-Majlessi I, Levy RH. A useful tool for drug interaction
evaluation: the University of Washington Metabolism and Transport Drug Interaction
Database. Hum Genomics. 2010 Oct;5(1) :61-72.
32. Prueksaritanont T, Chu X, Evers R, et al. Pitavastatin is a more sensitive and selective
organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin
Pharmacol. 2014 Sep;78(3) :587-98.
33. Vildhede A, Karlgren M, Svedberg EK, et al. Hepatic uptake of atorvastatin: influence
of variability in transporter expression on uptake clearance and drug-drug interactions.
Drug Metab Dispos. 2014 Jul;42(7) :1210-8.
34. Karlgren M, Vildhede A, Norinder U, et al. Classification of inhibitors of hepatic organic
anion transporting polypeptides (OATPs): influence of protein expression on drug-drug
interactions. J Med Chem. 2012 May 24;55(10) :4740-63.
35. Yoshikado T, Maeda K, Furihata S, et al. A Clinical Cassette Dosing Study for
Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.
Pharm Res. 2017 Aug;34(8) :1570-1583.
36. Akita H, Suzuki H, Ito K, et al. Characterization of bile acid transport mediated by
multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys
Acta. 2001 Mar 9;1511(1) :7-16.
112
37. Kuipers F, Enserink M, Havinga R, et al. Separate transport systems for biliary
secretion of sulfated and unsulfated bile acids in the rat. J Clin Invest. 1988
May;81(5) :1593-9.
38. Sasaki M, Suzuki H, Ito K, et al. Transcellular transport of organic anions across a
double-transfected Madin-Darby canine kidney II cell monolayer expressing both
human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug
resistance-associated
protein
(MRP2/ABCC2)
Biol
Chem.
2002
Feb
22;277(8) :6497-503.
39. Uegaki S, Takikawa H, Yamanaka M. Effect of organic anions and bile acid conjugates
on biliary excretion of taurine-conjugated bile acid sulfates in the rat. Steroids. 1999
Nov;64(11) :790-5.
40. van der Schoor LW, Verkade HJ, Kuipers F, Jonker JW. New insights in the biology of
ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opin Drug
Metab Toxicol. 2015 Feb;11(2) :273-93.
41. Xiang X, Han Y, Neuvonen M, et al. Effect of SLCO1B1 polymorphism on the plasma
concentrations of bile acids and bile acid synthesis marker in humans Pharmacogenet
Genomics. 2009 Jun;19(6) :447-57.
42. Thakare R, Alamoudi JA, Gautam N, et al. Species differences in bile acids I. Plasma
and urine bile acid composition. J Appl Toxicol. 2018 Oct;38(10) :1323-1335.
43. Han J, Liu Y, Wang R, Yang J, et al. Metabolic Profiling of Bile Acids in Human and
Mouse Blood by LC–MS/MS in Combination with Phospholipid-Depletion Solid-Phase
Extraction. Anal Chem. 2015 Jan 20;87(2) :1127-36.
44. Galeazzi R, Lorenzini I, Orlandi F. Rifampicin-induced elevation of serum bile acids in
man. Dig Dis Sci. 1980 Feb;25(2) :108-12.
113
45. Te Brake LH, Russel FG, van den Heuvel JJ, et al. Inhibitory potential of tuberculosis
drugs on ATP-binding cassette drug transporters. Tuberculosis. 2016 Jan;96:150-7.
46. Takashima T, Kitamura S, Wada Y, et al. PET imaging-based evaluation of
hepatobiliary transport in humans with (15R)-11C-TIC-Me. J Nucl Med. 2012
May;53(5) :741-8.
47. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: a molecular link between bile
acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005
Oct;25(10) :2020-30.
48. Gälman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal
variation that is asynchronous with cholesterol synthesis. Gastroenterology. 2005
Nov;129(5) :1445-53.
49. Chiang JYL. Bile acid metabolism and signaling in liver disease and therapy. Liver Res.
2017 Jun;1(1) :3-9.
50. Thakare R, Gao H, Kosa RE, et al. Leveraging of Rifampicin-Dosed Cynomolgus
Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers
for
Organic
Anion-Transporting
Drug
Polypeptides.
Metab
Dispos.
2017
Jul;45(7) :721-733.
51. Shen H, Yang Z, Mintier G, et al. Cynomolgus monkey as a potential model to assess
drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in
vivo,
and
in
vitro-to-in
vivo
extrapolation.
Pharmacol
Exp
Ther.
2013
Mar;344(3) :673-85.
52. Takahashi T, Ohtsuka T, Yoshikawa T, et al. Pitavastatin as an in vivo probe for
studying
hepatic
organic
anion
transporting
polypeptide-mediated
drug-drug
interactions in cynomolgus monkeys. Drug Metab Dispos. 2013 Oct;41(10) :1875-82.
114
53. Shen H, Su H, Liu T, et al. Evaluation of rosuvastatin as an organic anion transporting
polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in
cynomolgus monkeys. J Pharmacol Exp Ther. 2015 May;353(2) :380-91.
54. Davies B, Morris T. Physiological parameters in laboratory animals and humans.
Pharm Res. 1993 Jul;10(7) :1093-5.
55. P Koskelo, M Kekki. Multicompartment analysis of 14C-labelled coproporphyrin and
uroporphyrin kinetics in human beings. Ann Clin Res. 1976; 8 Suppl 17:198-202.
56. Sanoh S, Ohta S. Chimeric mice transplanted with human hepatocytes as a model for
prediction of human drug metabolism and pharmacokinetics. Biopharm Drug Dispos.
2014 Mar;35(2) :71-86.
57. Naritomi Y, Sanoh S, Ohta S. Chimeric mice with humanized liver: Application in drug
metabolism
and
pharmacokinetics
studies
for
drug
discovery.
Drug
Metab
Pharmacokinet. 2018 Feb;33(1) :31-39.
58. Uchida M, Tajima Y, Kakuni M, et al. Organic Anion-Transporting Polypeptide (OATP)
-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in
Chimeric Mice with Humanized Liver. Drug Metab Dispos. 2018 Jan;46(1) :11-19.
59. Tateno C, Yoshizane Y, Saito N, et al. Near Completely Humanized Liver in Mice Shows
Human-Type Metabolic Responses to Drugs Am J Pathol. 2004 Sep;165(3) :901-12.
60. Takehara I, Yoshikado T, Ishigame K, et al. Comparative Study of the Dose-Dependence
of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in
Healthy Volunteers. Pharm Res. 2018 May 10;35(7) :138.
61. Toshimoto K, Tomoda Y, Chiba K, Sugiyama Y. Analysis of the Change in the Blood
Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver
Considering the Enterohepatic Circulation: Examining Whether the Inhibition
115
Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the
Analyses Using Physiologically Based Pharmacokinetic Modeling. J Pharm Sci. 2017
Sep;106(9) :2727-2738.
62. Takehara I, Watanabe N, Mori D, et al. Effect of Rifampicin on the Plasma
Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted
Chimeric Mice
With or Without Bile Flow Diversion
J Pharm Sci. 2019
Aug;108(8) :2756-2764.
63. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs:
mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 Dec;80(6) :565-81.
64. Hirano M, Maeda K, Matsushima S, et al. Involvement of BCRP (ABCG2)
in the
biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3) :800-7.
65. Kanda K, Takahashi R, Yoshikado T, et al. Total hepatocellular disposition profiling of
rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes. Drug Metab
Pharmacokinet. 2018 Jun;33(3) :164-172.
66. Park JW, Siekmeier R, Lattke P, et al. Pharmacokinetics and pharmacodynamics of
fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc
Pharmacol Ther. 2001 Oct;6(4) :351-61.
67. Yoshikado T, Yoshida K, Kotani N, et al. Quantitative Analyses of Hepatic
OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling
With
Parameter
Optimization
Method.
Clin
Pharmacol
Ther.
2016
Nov;100(5) :513-523.
68. Prueksaritanont T, Tatosian DA, Chu X, et al. Validation of a microdose probe drug
cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
Clin Pharmacol Ther. 2017 Apr;101(4) :519-530.
116
69. Tomita Y, Maeda K, Sugiyama Y. Ethnic variability in the plasma exposures of
OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of
its mechanism. Clin Pharmacol Ther. 2013 Jul;94(1) :37-51.
70. Chan KM, Scott MG, Wu TW, et al. Inaccurate values for direct bilirubin with some
commonly used direct bilirubin procedures. Clin Chem. 1985 Sep;31(9) :1560-3.
71. Suga T, Yamaguchi H, Sato T, et al. Preference of Conjugated Bile Acids over
Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3. PLoS One. 2017
Jan 6;12(1) :e0169719.
72. Mori D, Kashihara Y, Yoshikado T, et al. Effect of OATP1B1 genotypes on plasma
concentrations of endogenous OATP1B1 substrates and drugs, and their association in
healthy volunteers. Drug Metab Pharmacokinet. 2019 Feb;34(1) :78-86.
73. Yee SW, Giacomini MM, Shen H, et al. Organic Anion Transporter Polypeptide 1B1
Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated
Biomarker Levels in Healthy Volunteers. Clin Transl Sci. 2019 Jul;12(4) :388-399.
74. Mori D, Kimoto E, Rago B, et al. Dose-Dependent Inhibition of OATP1B by Rifampicin
in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and
OATP1B Probe Drugs. Clin Pharmacol Ther. 2020 Apr;107(4) :1004-1013.
75. Yoshikado T, Toshimoto K, Maeda K, et al. PBPK Modeling of Coproporphyrin I as an
Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1
and OATP1B3. CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11) :739-747.
76. Asaumi R, Menzel K, Lee W, et al. Expanded Physiologically‐Based Pharmacokinetic
Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous
Biomarker
via
Complex
Mechanisms
Including
117
Organic
Anion
Transporting
Polypeptide
1B
Induction.
CPT
Pharmacometrics
Syst
Pharmacol.
2019
Nov;8(11) :845-857.
77. Takehara I, TerashimaH, Nakayama T, Yoshikado T, Yoshida M, Furihata K, et al.
Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide
as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and
OATP1B3 in Healthy Japanese Volunteers. Pharm Res. 2017 Aug;34(8) :1601-1614.
118
...
論文の公開元へ
